Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy

NCT02112838 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT02112838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02112838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
November 12, 2018
Enrollment
76 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy